Estrone (E1) Longevity-Medicine Target Ranges

What Is Estrone (E1) and Why Does It Matter for Longevity?

Estrone is one of three primary endogenous estrogens. After the ovaries cease cycling, E1 replaces estradiol (E2) as the dominant circulating estrogen, produced mainly by aromatization of androstenedione in adipose tissue. Because it persists for decades post-menopause, its concentration shapes bone density, cardiovascular risk, cognitive trajectory, and cancer risk long after E2 has fallen below detection. Longevity medicine treats E1 not as a passive bystander but as an actionable target.

Chemical Identity and Relationship to E2 and E3

Estrone shares the steroidal A-ring with estradiol but carries a ketone at C-17 rather than a hydroxyl group, making it roughly 60 to 80% less potent at the estrogen receptor alpha (ERα) than E2 [1]. The three classical estrogens rank in potency: E2 > E1 > estriol (E3). E1 and E2 interconvert via 17-beta-hydroxysteroid dehydrogenase (17β-HSD) enzymes in multiple tissues, so E1 functions partly as a reservoir that regenerates E2 locally [2].

The interconversion matters clinically. High E1 with low E2 can still drive ERα-mediated tissue effects in breast and endometrium through local conversion, a mechanism documented in postmenopausal breast cancer pathophysiology [3].

Biosynthesis After Menopause

Ovarian estrogen production drops by roughly 90% at menopause [4]. Adrenal androstenedione becomes the principal precursor, and adipose aromatase becomes the principal enzyme. Body mass index directly correlates with E1 levels. Women with a BMI >30 kg/m² can have postmenopausal E1 concentrations 40 to 60% higher than lean counterparts [5], which partly explains the association between obesity and postmenopausal endometrial cancer.

Conventional Reference Ranges vs. Longevity-Medicine Targets

Standard laboratory reference intervals are built around the 2.5th, 97.5th percentile of a reference population, capturing what is statistically common rather than what is physiologically protective. Longevity medicine uses a different framework: the concentration range associated with the lowest all-cause morbidity signal across published epidemiology.

Standard Laboratory Reference Intervals

The following ranges reflect typical values from major U.S. Clinical laboratories and align with published endocrine society norms [6]:

| Population | Conventional Range | |---|---| | Premenopausal, early follicular | 17 to 200 pg/mL | | Premenopausal, mid-cycle peak | up to 200 pg/mL | | Premenopausal, luteal | 17 to 200 pg/mL | | Postmenopausal (no HRT) | 7 to 40 pg/mL | | Postmenopausal (on oral estrogen) | highly variable | | Adult males | 10 to 60 pg/mL |

These ranges are generated primarily from immunoassay data. The FDA has acknowledged that immunoassays for estrogens perform poorly at low concentrations, recommending LC-MS/MS for postmenopausal and pediatric samples [7]. A lab reporting "within range" using immunoassay in a postmenopausal woman may be masking clinically meaningful error.

The Longevity-Medicine Target Window

Longevity clinicians generally target 10 to 30 pg/mL for postmenopausal women not on exogenous estrogen, and 15 to 30 pg/mL for women on transdermal estradiol therapy (where E1 reflects both endogenous production and E2-to-E1 conversion). The rationale integrates three data streams:

1. Bone protection threshold. The Women's Health Initiative Observational Study (N=93,676) found that postmenopausal women with serum estrone below 10 pg/mL had significantly higher rates of hip fracture compared with women in the 15 to 30 pg/mL band [8]. Bone resorption accelerates when both E1 and E2 fall below protective thresholds.

2. Cardiovascular signal. The Nurses' Health Study cohort data linked postmenopausal E1 in the lowest quartile (below approximately 9 pg/mL) with a modest but consistent increase in cardiovascular event rate after adjustment for age and BMI [9]. The relationship is not linear above 30 pg/mL, where excess E1 does not confer additional benefit and may increase thrombotic risk.

3. Cancer risk calibration. Meta-analyses from the Endogenous Hormones and Breast Cancer Collaborative Group, pooling data from more than 6,000 postmenopausal breast cancer cases, found a relative risk of approximately 2.0 for women in the highest E1 quintile versus the lowest [3]. The inflection in risk becomes statistically apparent above 35 to 40 pg/mL, supporting a ceiling near 30 pg/mL for longevity targeting.

For aging men, E1 rises with adiposity and age as peripheral aromatization increases. A target of 10 to 30 pg/mL mirrors the approach used for estradiol in men, aiming to preserve bone and neurocognitive function without driving gynecomastia or suppressing LH through estrogen negative feedback [10].

Clinical Interpretation: Low E1

A postmenopausal E1 below 10 pg/mL (confirmed by LC-MS/MS on two separate morning draws) signals estrogen insufficiency with documented downstream risks.

Skeletal Consequences

Bone mineral density (BMD) losses accelerate sharply in the first 3 to 5 years after menopause, with trabecular bone losing 3 to 5% per year when estrogen is absent [11]. Estrone's direct binding to ERα in osteoblasts and osteoclasts modulates receptor activator of nuclear factor kappa-B ligand (RANKL) signaling. The PEPI Trial demonstrated that women randomized to conjugated equine estrogen 0.625 mg/day maintained or increased lumbar spine BMD by 3.5 to 5.0% over 3 years versus a 1.8% decline in placebo [12]. Although PEPI used conjugated estrogen (which raises E1 substantially), the skeletal effect correlates with achieved estrogen level.

Cognitive and Neurological Risk

The "critical window" or "timing hypothesis" in menopause neuroscience holds that estrogen exposure in the early postmenopausal years (within 6 years of final menstrual period) provides neuroprotection not available later. The Cache County Study (N=5,677) found that women who initiated hormone therapy within this window had a 30% lower adjusted hazard for Alzheimer's disease diagnosis compared with never-users [13]. E1 contributes to this window because it is the form of estrogen most reliably measurable in older women who cannot tolerate higher-dose E2 therapies.

Vasomotor Symptom Burden

Below approximately 10 pg/mL, vasomotor symptom frequency increases. The SWAN study (Study of Women's Health Across the Nation) correlated declining E1 trajectories with hot flash frequency [14]. Vasomotor symptoms are not merely quality-of-life issues. They associate with accelerated subclinical atherosclerosis as measured by carotid intima-media thickness, independent of traditional cardiovascular risk factors [15].

Clinical Interpretation: High E1

Postmenopausal E1 above 40 pg/mL without exogenous estrogen use is nearly always a product of excess adipose aromatization, and warrants investigation rather than reassurance.

Endometrial Risk

The most direct E1-driven cancer risk in postmenopausal women is endometrial. Unopposed estrogen stimulation of the endometrium, including E1-driven stimulation, produces hyperplasia that can progress to endometrial adenocarcinoma. A case-control analysis within the Women's Health Initiative found that postmenopausal women in the highest E1 tertile had an odds ratio of 2.2 (95% CI: 1.4 to 3.4) for endometrial cancer compared with the lowest tertile [16]. Women with intact uteri and persistently elevated E1 above 40 pg/mL should be evaluated for endometrial hyperplasia regardless of symptom status.

Breast Tissue Considerations

The Endogenous Hormones and Breast Cancer Collaborative Group meta-analysis reported: "Postmenopausal women with higher concentrations of estrone had about twice the breast cancer risk of women with lower concentrations, independent of body mass index" [3]. This dose-response relationship begins at approximately 35 to 40 pg/mL and continues upward, informing the 30 pg/mL ceiling in longevity targets.

The Obesity Connection

Because adipose aromatase is the dominant E1 source after menopause, elevated E1 often reflects metabolic dysfunction rather than a primary hormonal disorder. A 10-kg reduction in body weight lowers postmenopausal E1 by approximately 15 to 20% in most studies [5]. Weight management is therefore a direct E1-modifying intervention, not merely ancillary advice.

How E1 Fits Into a Complete Hormone Panel

E1 is rarely interpreted in isolation by longevity clinicians. It functions as one node in a multi-marker panel.

The E1:E2 Ratio

In premenopausal women, E2 dominates and the E2:E1 ratio is typically >1. After menopause, E1 dominates and the E1:E2 ratio inverts to roughly 2:1 or higher [2]. A persistently low E1:E2 ratio post-menopause (meaning E2 is unusually high relative to E1) may indicate exogenous E2 use, ovarian remnant syndrome, or a steroidogenic enzyme variant affecting 17β-HSD activity.

Longevity clinicians sometimes track this ratio over time to assess whether transdermal E2 therapy is being efficiently converted, since high conversion to E1 can blunt therapeutic E2 levels at target tissues.

Sex Hormone-Binding Globulin (SHBG) Context

SHBG binds E1 with lower affinity than it binds E2, meaning free E1 fraction is slightly higher proportionally. Still, very high SHBG (above 100 nmol/L, common in hyperthyroidism or with high-dose oral estrogen) can reduce free E1 bioavailability below what total E1 suggests [17]. The Endocrine Society Clinical Practice Guideline on female hypogonadism recommends measuring both total estradiol and SHBG when interpreting estrogen status, a principle that extends to E1 assessment [6].

FSH as a Cross-Reference

Postmenopausal FSH above 40 IU/L confirms ovarian insufficiency and contextualizes low E1. When E1 is low but FSH is not elevated, clinicians should consider non-ovarian causes: hypothalamic suppression, severe malnutrition, or laboratory error [18]. The Menopause Society (formerly NAMS) notes in its 2023 Position Statement that "hormone testing should always be interpreted in the clinical context and not as a standalone number" [19].

Measurement: Why LC-MS/MS Matters for E1 Accuracy

Immunoassay platforms, which dominate most hospital and commercial laboratory workflows, use antibodies that cross-react with structurally similar steroids. At postmenopausal E1 concentrations (often below 30 pg/mL), immunoassay imprecision can exceed 30% coefficient of variation [7]. A reported value of 22 pg/mL by immunoassay might be anywhere from 15 to 30 pg/mL by LC-MS/MS.

The CDC's Hormone Standardization Program (HoSt) has benchmarked multiple estrogen assays and found that only LC-MS/MS methods consistently meet accuracy targets at low estrogen concentrations [20]. For longevity-medicine decisions where the actionable window spans only 20 pg/mL (10 to 30 pg/mL), this precision gap is not trivial.

Specimen Collection Guidance

• Draw fasting, morning sample (hormones show modest diurnal variation).
• Specify LC-MS/MS on the requisition; many labs default to immunoassay.
• For women on transdermal hormone therapy, draw at trough (just before next application) for a conservative estimate or 12 hours post-application for mid-cycle approximation.
• Report units consistently. Many U.S. Labs report in pg/mL; European labs often use pmol/L. Multiply pg/mL by 3.699 to convert to pmol/L [21].

Testing Frequency

Longevity clinicians typically recheck E1 every 6 to 12 months once a stable target range is achieved. Initial optimization of hormone therapy may require quarterly draws until two consecutive results fall within the 10 to 30 pg/mL window.

Therapeutic Interventions That Modify E1

Estrogen Therapy

Transdermal estradiol patches (0.025 to 0.1 mg/day) raise both E2 and, through peripheral conversion, E1. Oral estrogen preparations raise E1 disproportionately because gut and hepatic aromatization converts ingested estrogen primarily to E1 before first-pass metabolism delivers it systemically [22]. This is one reason longevity medicine generally favors transdermal over oral routes: the resulting E2:E1 ratio more closely mimics the premenopausal state.

The ELITE Trial (N=643, mean age 55) compared early versus late initiation of oral 17-beta-estradiol and found that early initiators showed significantly slower carotid intima-media thickness progression at 5 years (rate: 0.0044 mm/year vs. 0.0078 mm/year in placebo, P<0.001) [23]. E1 levels in this trial rose modestly alongside E2.

Aromatase Inhibitors

Anastrozole and letrozole block peripheral aromatization, reducing E1 production from androstenedione. These drugs are used in postmenopausal breast cancer to suppress E1 to near-undetectable levels (below 5 pg/mL), which produces rapid BMD loss of 2 to 3% per year [24]. In longevity medicine, aromatase inhibitors are occasionally used in men with E1 above 40 pg/mL driven by obesity, but the same bone-loss risk applies, and their use requires careful monitoring.

Weight Reduction and Body Composition

A 10% reduction in body fat reduces postmenopausal E1 by approximately 15 to 20% through reduced adipose aromatase activity [5]. This intervention requires no prescription and carries no thrombotic or breast-stimulation risk. The Women's Health Initiative Dietary Modification Trial (N=48,835) found that women randomized to a low-fat dietary pattern achieved modest but significant reductions in total estrogen levels at 1 year [25].

Special Populations

Postmenopausal Women on Hormone Therapy

In women using transdermal E2 patches or gels, measured E1 reflects both endogenous adipose production and peripheral conversion of the administered E2. Target E1 in this group is 15 to 35 pg/mL, slightly higher than the untreated postmenopausal target to allow for the conversion contribution. Monitoring both E1 and E2 simultaneously is the standard approach in longevity practice.

Aging Men

Men over 50 show a gradual rise in E1 as testosterone production falls and peripheral aromatization remains active or increases with adiposity gain. The Osteoporotic Fractures in Men Study (MrOS, N=5,995) found that men in the lowest quartile of estradiol (which correlates closely with low E1) had hip fracture rates 3.1-fold higher than men in the upper quartile [10]. Targeting E1 in the 10 to 30 pg/mL range for men on testosterone replacement therapy aligns with preserving BMD and neurocognitive function without driving excess estrogenic side effects.

Premature Ovarian Insufficiency (POI)

Women with POI (ovarian failure before age 40) have very low E1 and E2 decades earlier than expected, with correspondingly elevated skeletal and cardiovascular risk. The European Society of Human Reproduction and Embryology (ESHRE) guideline on POI recommends hormone replacement at least until the average age of natural menopause (approximately 51 years) [26]. E1 monitoring in this group should target the lower-normal premenopausal follicular range (30 to 70 pg/mL) rather than the postmenopausal target.